These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27452262)

  • 1. Comparing the sensitivity of linear and volumetric MRI measurements to detect changes in the size of vestibular schwannomas in patients with neurofibromatosis type 2 on bevacizumab treatment.
    Morris KA; Parry A; Pretorius PM
    Br J Radiol; 2016 Sep; 89(1065):20160110. PubMed ID: 27452262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.
    Sponghini AP; Platini F; Rondonotti D; Soffietti R
    Tumori; 2015 Nov; 101(6):e167-70. PubMed ID: 26108240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
    Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
    J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
    Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
    J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: A volumetric consideration.
    Picry A; Bonne NX; Ding J; Aboukais R; Lejeune JP; Baroncini M; Dubrulle F; Vincent C
    Laryngoscope; 2016 Oct; 126(10):2358-62. PubMed ID: 27075822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
    Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
    Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II.
    Harris GJ; Plotkin SR; Maccollin M; Bhat S; Urban T; Lev MH; Slattery WH
    Neurosurgery; 2008 Jun; 62(6):1314-9; discussion 1319-20. PubMed ID: 18824998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Segmental schwannomatosis in upper-extremity: 5 cases report and literature review].
    Wang ZX; Chen SL; Yi CJ; Li C; Rong YB; Tian GL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Oct; 45(5):698-703. PubMed ID: 24136261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
    Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
    Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.
    Li KL; Djoukhadar I; Zhu X; Zhao S; Lloyd S; McCabe M; McBain C; Evans DG; Jackson A
    Neuro Oncol; 2016 Feb; 18(2):275-82. PubMed ID: 26311690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities.
    Sverak P; Adams ME; Haines SJ; Levine SC; Nascene D; Sommer K; Dusenbery K; Huang TC; Moertel C
    Otolaryngol Head Neck Surg; 2019 Mar; 160(3):526-532. PubMed ID: 30373466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.
    Plotkin SR; Bredella MA; Cai W; Kassarjian A; Harris GJ; Esparza S; Merker VL; Munn LL; Muzikansky A; Askenazi M; Nguyen R; Wenzel R; Mautner VF
    PLoS One; 2012; 7(4):e35711. PubMed ID: 22558206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports.
    Goutagny S; Kalamarides M
    Neurochirurgie; 2018 Nov; 64(5):370-374. PubMed ID: 28162254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schwannomatosis: a new member of neurofibromatosis family.
    Chen SL; Liu C; Liu B; Yi CJ; Wang ZX; Rong YB; Zhu J; Ding Y; Tian GL
    Chin Med J (Engl); 2013 Jul; 126(14):2656-60. PubMed ID: 23876891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
    Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
    J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Available Therapies for Patients with Neurofibromatosis-Related Nervous System Tumors.
    Strowd RE
    Curr Treat Options Oncol; 2020 Aug; 21(10):81. PubMed ID: 32767156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple cutaneous plexiform schwannomas. Report of a case and review of the literature with particular reference to the association with types 1 and 2 neurofibromatosis and schwannomatosis.
    Reith JD; Goldblum JR
    Arch Pathol Lab Med; 1996 Apr; 120(4):399-401. PubMed ID: 8619756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of primary vestibular schwannoma cultures from neurofibromatosis type-2 patients.
    Hung G; Faudoa R; Li X; Xeu Z; Brackmann DE; Hitselberg W; Saleh E; Lee F; Gutmann DH; Slattery W; Rhim JS; Lim D
    Int J Oncol; 1999 Mar; 14(3):409-15. PubMed ID: 10024671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
    Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
    Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Diagnostic Dilemma: Multiple Primary Intracranial Tumors Without Vestibular Schwannomas.
    Faucett EA; Larsen BT; Khan R; Chiu AG; Chang EH
    Ann Otol Rhinol Laryngol; 2016 Nov; 125(11):938-942. PubMed ID: 27553596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.